Compare Avient Corporation (AVNT) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avient Corporation vs Novavax Inc — how do they compare? Avient Corporation trades at $45.2 (market cap $4.17B), while Novavax Inc trades at $7.95 (market cap $1.31B). The key difference: Avient Corporation is far larger — about 3.2× Novavax Inc's market cap, and Avient Corporation pays a 2.42% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| AVNT | NVAX | |
|---|---|---|
Market Cap | $4.17B | $1.31B |
Sector | Technology | Health |
52-Week High | $45.69 | $11.19 |
52-Week Low | $27.48 | $6.22 |
Enterprise Value | $5.62B | $889.30M |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVNT trades at $45.33, down 0.7% today, with a bullish technical signal from moving averages but overbought RSI levels. The company reported strong Q2 2026 earnings of $0.96 per share, beating estimates, and raised full-year guidance. Revenue growth of 5.8% to $917 million reflects robust demand and operational efficiency. Analysts maintain a buy consensus with a $49.00 price target, citing momentum and value metrics.
Outlook is positive due to consistent earnings beats and dividend payments, but risks include high valuation (P/E 24.55) and potential margin pressure from input costs. Investors should monitor Q3 2026 results against the $0.79 EPS estimate for sustained growth confirmation.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Avient Corporation
Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Read more on AVNT →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
